Skip to main content

Table 2 Results of HTS of CSC with 19 FDA-approved oncology drugs

From: Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening

NSC Name % growth SD (%) p-value p-adj GI 50OVCAR3 (−log10)
3053 Dactinomycin 8.4 3.9 1.38E-08 1.07E-05 8.54
24559 Plicamycin 10.8 3.6 9.91E-11 7.86E-08 7.35
67574 Vincristine 27.0 6.0 1.21E-06 8.74E-04 7.68
14229 Mepacrine 37.6 6.1 9.93E-08 7.56E-05 5.55
49842 Vinblastine 49.1 10.6 2.34E-05 1.56E-02 9.71
125066 Bleomycin 53.0 10.2 1.10E-05 7.54E-03 5.28
63878 Cytarabine 76.6 11.0 1.04E-02 1 5.00
105014 Cladribine 82.7 17.0 7.13E-02 1 4.59
755 Mercaptopurine 95.2 8.4 2.83E-01 1 5.94
740 Methotrexate 96.7 30.8 8.38E-01 1 6.69
226080 Rapamycin 97.0 20.9 7.93E-01 1 8.17
296961 Amifostine 99.4 12.0 9.18E-01 1 3.13
85998 Streptozocin 103.7 28.9 8.10E-01 1 3.14
32065 Hydroxyurea 107.4 14.8 2.38E-01 1 2.92
180973 Tamoxifen 115.1 14.3 4.45E-02 1 5.23
750 Busulfan 120.6 15.9 3.65E-02 1 3.60
38721 Mitotane 128.2 47.6 2.68E-01 1 4.73
9706 Triethylenemelamine 128.9 82.5 5.26E-01 1 4.74
45388 Dacarbazine 164.3 14.2 4.46E-04 2.68E-01 4.25